Eledon Pharmaceuticals has reported its first quarter 2026 financial results and recent business highlights. The company has also announced updates on its investigational treatment for type 1 diabetes, with some reports suggesting that a number of patients have been able to stop using insulin after receiving islet transplants. However, there is some uncertainty regarding the details of these developments, with conflicting information available from different sources.